

Data Supplement

BNT162b2 COVID-19 VACCINATION AND ITS EFFECT ON BLOOD PRESSURE

Toh Leong Tan^{1*,#a}, Sharifah Azura Salleh^{2,#a}, Zuraidah Che Man^{1,#a}, Michelle Hwee Peng Tan^{3,a},
Rashid Kader^{4,#a}, Razman Jarmin^{5,#a}.

1. Department of Emergency Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia
2. Department of Medical Microbiology and Immunology, Faculty of Medicine, Universiti Kebangsaan Malaysia
3. Pharmacy Department, Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia
4. Staff Polyclinic, Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia
5. Department of Surgery, Faculty of Medicine, Universiti Kebangsaan Malaysia

#a Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia, 56000 Cheras, Kuala Lumpur, Malaysia.

*Corresponding Author

Email: sebastianttl@yahoo.co.uk

CONTENT

| List | Content | Page |
|------------------|--|------|
| Figure S1 | Study population for BNT162b2 vaccines. | 3 |
| Table S1 | Detail Demography of the Vaccinees Who Had a History of Hypertension | 4 |
| Table S2 | Frequencies Of Adverse Events for Immunisation After Both Doses of Vaccination and Their Association with Blood Pressure | 5 |




Figure S1. Study population for BNT162b2 vaccines.

THE BNT162b2 COVID-19 VACCINATION AND THE EFFECT ON BLOOD PRESSURE

Table S1. Detail Demography of the Vaccinees Who Had a History of Hypertension under Treatment

| Age, years | Gender | First Dose of Vaccine Blood Pressure, mmHg | | | | Second Dose of Vaccine Blood Pressure, mmHg | | | |
|------------|--------|--|---------------------|----------------------|----------------------|---|---------------------|----------------------|----------------------|
| | | Pre-vaccination SBP | Pre-vaccination DBP | Post-vaccination SBP | Post-vaccination DBP | Pre-vaccination SBP | Pre-vaccination DBP | Post-vaccination SBP | Post-vaccination DBP |
| 56-60 | Male | 187 | 78 | 152 | 54 | 164 | 78 | 164 | 77 |
| 46-50 | Male | 151 | 94 | 151 | 96 | 172 | 99 | 174 | 98 |
| 46-50 | Female | 140 | 71 | 150 | 93 | 139 | 93 | 133 | 96 |
| 41-45 | Female | 159 | 91 | 156 | 95 | 114 | 73 | 124 | 79 |
| 56-60 | Female | 155 | 87 | 156 | 85 | 145 | 83 | 145 | 89 |
| 41-45 | Female | 145 | 91 | 149 | 84 | 136 | 81 | 124 | 77 |
| 41-45 | Female | 108 | 79 | 103 | 71 | 140 | 79 | 144 | 105 |
| 41-45 | Female | 134 | 88 | 130 | 86 | 139 | 90 | 134 | 91 |

Table S2. Frequencies Of Adverse Events for Immunisation After Both Doses of Vaccination and Their Association with Blood Pressure

| | Adverse Event for Immunisation (n=287) | Dose 1, n (%) | Systolic increase more than 20mmHg, P-value | Diastolic increase more than 10mmHg, P-value | Dose 2, n (%) | Systolic increase more than 20mmHg, P-value | Diastolic increase more than 10mmHg, P-value |
|----|---|----------------------|--|---|----------------------|--|---|
| 1 | Pain over the Injection Site | 52 (18.1) | 0.47 ^a | 0.46 ^a | 60 (20.9) | 0.28 ^a | 0.83 ^b |
| 2 | Numbness over the Injection Site | 34 (11.8) | 0.27 ^a | 0.40 ^a | 21 (7.3) | 0.50 ^a | 0.13 ^a |
| 3 | Fatigue | 18 (6.3) | 0.63 ^a | 0.66 ^a | 4 (1.4) | 0.88 ^a | 0.68 ^a |
| 4 | Giddiness | 11 (3.8) | 0.11 ^a | 0.54 ^a | 22 (7.7) | 0.52 ^a | 0.62 ^a |
| 5 | Headache | 5 (1.7) | 0.76 ^a | 0.71 ^a | 4 (1.4) | 0.88 ^a | 0.68 ^a |
| 6 | Nausea | 4 (1.4) | 0.80 ^a | 0.24 ^a | 3 (1.0) | 0.91 ^a | 0.75 ^a |
| 7 | Near Fainting | 1 (0.3) | 0.95 ^a | 0.07 ^a | 1 (0.3) | 0.97 ^a | 0.91 ^a |
| 8 | Difficulty in Breathing | 1 (0.3) | 0.95 ^a | 0.07 ^a | 0 (0) | - | - |
| 9 | Body Itchiness | 0 (0.0) | - | - | 1(0.3) | 0.97 ^a | 0.09 ^a |
| 10 | No AEFI | 161(56.1) | 0.45 ^b | 0.07 ^b | 171 (59.6) | 0.27 ^a | 0.20 ^b |

^a Fisher's Exact Test

^b Chi's Square Test

*p-value less than 0.05 is considered statistically significant.